Cornelia de Lange综合征(Cornelia de Lange syndrome,CdLS)在1933年由荷兰儿科医生Cornelia首次描述,该病是一种伴有多系统发育异常的遗传缺陷综合征,呈常染色体显性或X连锁显性方式遗传,发病率介于1/10000~1/30000活产新生儿,常表现...Cornelia de Lange综合征(Cornelia de Lange syndrome,CdLS)在1933年由荷兰儿科医生Cornelia首次描述,该病是一种伴有多系统发育异常的遗传缺陷综合征,呈常染色体显性或X连锁显性方式遗传,发病率介于1/10000~1/30000活产新生儿,常表现为成比例的身材矮小、宫内及出生后发育迟缓、特定的面部特征、多器官系统畸形(特别是心脏、胃肠道和肌肉骨骼系统)以及认知和行为方面的异常等。该病常见的突变基因有NIPBL、SMC1A、SMC3、RAD21、BRD4、HDAC8和ANKRD11,所有这些基因表达的蛋白都参与组成黏连蛋白复合物或影响其调节功能[1-2]。本团队对1例CdLS患儿及其家系成员进行基因突变检测,发现患儿携带HDAC8基因c.111+3A>T新发突变,既往未见报道,并统计中国目前报道的HDAC8基因突变所致CdLS患者基因型及临床表现,具体报告如下。展开更多
Increasing evidence showed that histone deacetylase 6(HDAC6)dysfunction is directly associated with the onset and progression of various diseases,especially cancers,making the development of HDAC6-targeted anti-tumor ...Increasing evidence showed that histone deacetylase 6(HDAC6)dysfunction is directly associated with the onset and progression of various diseases,especially cancers,making the development of HDAC6-targeted anti-tumor agents a research hotspot.In this study,artificial intelligence(AI)technology and molecular simulation strategies were fully integrated to construct an efficient and precise drug screening pipeline,which combined Voting strategy based on compound-protein interaction(CPI)prediction models,cascade molecular docking,and molecular dynamic(MD)simulations.The biological potential of the screened compounds was further evaluated through enzymatic and cellular activity assays.Among the identified compounds,Cmpd.18 exhibited more potent HDAC6 enzyme inhibitory activity(IC_(50)=5.41 nM)than that of tubastatin A(TubA)(IC_(50)=15.11 nM),along with a favorable subtype selectivity profile(selectivity index z 117.23 for HDAC1),which was further verified by the Western blot analysis.Additionally,Cmpd.18 induced G2/M phase arrest and promoted apoptosis in HCT-116 cells,exerting desirable antiproliferative activity(IC_(50)=2.59 mM).Furthermore,based on long-term MD simulation trajectory,the key residues facilitating Cmpd.18's binding were identified by decomposition free energy analysis,thereby elucidating its binding mechanism.Moreover,the representative conformation analysis also indicated that Cmpd.18 could stably bind to the active pocket in an effective conformation,thus demonstrating the potential for in-depth research of the 2-(2-phenoxyethyl)pyridazin-3(2H)-one scaffold.展开更多
文摘Cornelia de Lange综合征(Cornelia de Lange syndrome,CdLS)在1933年由荷兰儿科医生Cornelia首次描述,该病是一种伴有多系统发育异常的遗传缺陷综合征,呈常染色体显性或X连锁显性方式遗传,发病率介于1/10000~1/30000活产新生儿,常表现为成比例的身材矮小、宫内及出生后发育迟缓、特定的面部特征、多器官系统畸形(特别是心脏、胃肠道和肌肉骨骼系统)以及认知和行为方面的异常等。该病常见的突变基因有NIPBL、SMC1A、SMC3、RAD21、BRD4、HDAC8和ANKRD11,所有这些基因表达的蛋白都参与组成黏连蛋白复合物或影响其调节功能[1-2]。本团队对1例CdLS患儿及其家系成员进行基因突变检测,发现患儿携带HDAC8基因c.111+3A>T新发突变,既往未见报道,并统计中国目前报道的HDAC8基因突变所致CdLS患者基因型及临床表现,具体报告如下。
基金funded by Central Guidance on Local Science and Technology Development Fund of Hebei Province,China(Grant No.:226Z2605G)the Key Project from Hebei Provincial Department of Science and Technology,China(Grant No.:21372601D)+6 种基金Graduate Student Innovation Grant Program of Hebei Medical University,China(Grant No.:XCXZZB202303)Science Research Project of Hebei Education Department,China(Grant Nos.:BJ2025046,and CYZD202501)Program for Young Scientists in the Field of Natural Science of Hebei Medical University,China(Program Nos.:CYCZ2023010,CYCZ2023011,CYQD2021011,CYQD2021015 and CYQD2023012)Traditional Chinese Medicine Administration Project of Hebei Province,China(Project No.:2025427)National Natural Science Foundation of China(Grant No.:32100771)the Hebei Provincial Medical Science Research Project Plan,China(Project Nos.:20240241 and 20220200)Shijiazhuang Science and Technology Bureau,China(Grant Nos.:241200487A,and 07202204).
文摘Increasing evidence showed that histone deacetylase 6(HDAC6)dysfunction is directly associated with the onset and progression of various diseases,especially cancers,making the development of HDAC6-targeted anti-tumor agents a research hotspot.In this study,artificial intelligence(AI)technology and molecular simulation strategies were fully integrated to construct an efficient and precise drug screening pipeline,which combined Voting strategy based on compound-protein interaction(CPI)prediction models,cascade molecular docking,and molecular dynamic(MD)simulations.The biological potential of the screened compounds was further evaluated through enzymatic and cellular activity assays.Among the identified compounds,Cmpd.18 exhibited more potent HDAC6 enzyme inhibitory activity(IC_(50)=5.41 nM)than that of tubastatin A(TubA)(IC_(50)=15.11 nM),along with a favorable subtype selectivity profile(selectivity index z 117.23 for HDAC1),which was further verified by the Western blot analysis.Additionally,Cmpd.18 induced G2/M phase arrest and promoted apoptosis in HCT-116 cells,exerting desirable antiproliferative activity(IC_(50)=2.59 mM).Furthermore,based on long-term MD simulation trajectory,the key residues facilitating Cmpd.18's binding were identified by decomposition free energy analysis,thereby elucidating its binding mechanism.Moreover,the representative conformation analysis also indicated that Cmpd.18 could stably bind to the active pocket in an effective conformation,thus demonstrating the potential for in-depth research of the 2-(2-phenoxyethyl)pyridazin-3(2H)-one scaffold.
